Triple Helix Discovery Engine
2. Industry_Business Architects & Consolidators
Industry: By Sector
Intermediaries: Risk Capital (Angel, Seed, Venture Capital, SPAC, Strategic Corporate, Private Equity, Banking)
Intermediaries: Hedge Funds
*Hedge Funds (Medical, Biotechnology Focused)
Scopia Capital
Finance & Acquisitions: Scopia
Zogenix (NASDAQ: ZGNX)

Organization & Developments: Zogenix

Parents

*Development and commercialization of medicines to treat CNS disorders and pain
*DosePro device, a needle-free injection system for its sumatriptan pain management drug.
*Initial focus is the late-stage development and commercialization of Intraject® sumatriptan
*Needle-free, single-use, disposable, subcutaneous delivery system that will compete in the $2.5 billion triptan segment of the m
2011: Zogenix Strategy Unfolds as it Unveils Plans for Next Drug-and-Device Combo (2011)
2013: FDA Delay on New Drug Triggers Layoffs at San Diego’s Zogenix
2017: Zogenix' ZX008 Is The Real Deal - Zogenix, Inc. (NASDAQ:ZGNX)
2018: Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
2019: Buying Zogenix Stock On The Recent Dip: A Miraculous Effect In Treating Refractory Seizures Due To Childhood Orphan Epilepsies_seekingalpha.com
2019: FDA Refuses to Review Zogenix Seizure Drug, Says File Not Complete
2019: Zogenix Gets Much-Needed FDA Reversal As It Looks To Tackle Major Competitor - Zogenix, Inc. (NASDAQ:ZGNX)
2020: Zogenix Has A Wide Margin Of Safety After A 60% Sell-Off
2020: Zogenix: A Critical Launch
2020: Zogenix: A Rich Bet On Poor Investor Sentiment And Exaggerated Commercialization Concerns
2021: Zogenix, Inc.: Still Cautiously Optimistic
2021: Zogenix: Our Current Take On This 'Battleground' Biopharma Stock